Skip to content

Study · Randomized controlled trial · 1991

3 results

Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery.

Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL

Circulation1 Nov 1991Cited by 109 (Europe PMC)

PMID1934382 (opens in a new tab)DOI10.1161/01.cir.84.5.2063 (opens in a new tab)PepBankPUB-01934382
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In cardiac surgery patients, desmopressin did not decrease blood loss over 12 hours.

    In plain wordsIn cardiac surgery patients, desmopressin did not decrease blood loss over 12 hours.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood loss over 12 hours
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    0.3 micrograms/kg over 20 minutesAs given in this study (human).

    Source sentences

    Summary
    Desmopressin decreased neither the 12-hour blood loss nor the amount of homologous red cells transfused.
    2 context sentences
    Summary · context
    A double-blinded design randomly allocated 163 adult patients undergoing coronary revascularization, valve replacement, both procedures, or repair of atrial septal defect to four treatment groups:
    Summary · context
    desmopressin given as 0.3 micrograms/kg over 20 minutes after protamine infusion, and both drugs.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In cardiac surgery patients, desmopressin did not decrease homologous red cell transfusions.

    In plain wordsIn cardiac surgery patients, desmopressin did not decrease donor red cell transfusions.

    Peptide
    Desmopressin
    Outcome
    No significant changeHomologous red cell transfusion
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    0.3 micrograms/kg over 20 minutesAs given in this study (human).

    Source sentences

    Summary
    Desmopressin decreased neither the 12-hour blood loss nor the amount of homologous red cells transfused.
    2 context sentences
    Summary · context
    A double-blinded design randomly allocated 163 adult patients undergoing coronary revascularization, valve replacement, both procedures, or repair of atrial septal defect to four treatment groups:
    Summary · context
    desmopressin given as 0.3 micrograms/kg over 20 minutes after protamine infusion, and both drugs.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In cardiac surgery patients, adding desmopressin did not enhance the reduction in blood loss from tranexamic acid alone.

    In plain wordsIn cardiac surgery patients, adding desmopressin did not improve blood loss reduction compared with tranexamic acid alone.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood loss over 12 hours with tranexamic acid background
    Study

    n: not reported in source

    Comparator
    Tranexamic acid alone
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    0.3 micrograms/kg over 20 minutesAs given in this study (human).

    Source sentences

    Summary
    Tranexamic acid alone significantly reduced 12-hour blood loss, by 30% (mean, 318 versus 453 ml; p less than 0.0001), without enhancement by desmopressin.
    2 context sentences
    Summary · context
    A double-blinded design randomly allocated 163 adult patients undergoing coronary revascularization, valve replacement, both procedures, or repair of atrial septal defect to four treatment groups:
    Summary · context
    desmopressin given as 0.3 micrograms/kg over 20 minutes after protamine infusion, and both drugs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.